Medistim (MEDI.OL) Stock Analysis & AI Equity Report
Medistim (MEDI.OL) overview
Medistim (MEDI.OL) stock analysis and AI equity research. For the latest completed financial year, 2025, Medistim reported revenue of NOK 700m and operating profit of NOK 196m; the year-end share price was 259.00 NOK and market capitalisation was NOK 4,734m. Medistim is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Medistim's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-06. Data will be refreshed during report generation.
About Medistim
Medistim ASA develops and markets intraoperative surgical guidance systems and related consumables for cardiac, vascular and transplant surgery. Its MiraQ platform combines transit time flow measurement and high-frequency ultrasound imaging to help surgeons assess blood flow and tissue conditions during procedures. The company also distributes selected medical devices through Nordic sales operations.
Generate the Medistim report
Medistim is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Medistim and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.